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Abstract Alzheimer’sdisease(AD)isoneofthemost
common causes of dementia in the world. Patients with
AD frequently complain of vision disturbances that do
not manifest as changes in routine ophthalmological
examination ﬁndings. The main causes of these distur-
bances are neuropathological changes in the visual
cortex, although abnormalities in the retina and optic
nerve cannot be excluded. Pattern electroretinogram
(PERG) and pattern visual evoked potential (PVEP)
tests are commonly used in ophthalmology to estimate
bioelectrical function of the retina and optic nerve. The
aim of this study was to determine whether retinal and
optic nerve function, measured by PERG and PVEP
tests,ischangedinindividualsintheearlystagesofAD
with normal routine ophthalmological examination
results.StandardPERGandPVEPtestswereperformed
in30eyesof30patientswiththeearlystagesofAD.The
results were compared to 30 eyes of 30 normal healthy
controls. PERG and PVEP tests were recorded in
accordance with the International Society for Clinical
Electrophysiology of Vision (ISCEV) standards. Addi-
tionally, neural conduction was measured using retino-
cortical time (RCT)—the difference between P100-
wave latency in PVEP and P50-wave implicit time in
PERG. In PERG test, PVEP test, and RCT, statistically
signiﬁcant changes were detected. In PERG examina-
tion, increased implicit time of P50-wave (P\0.03)
and amplitudes reductions in P50- and N95-waves
(P\0.0001) were observed. In PVEP examination,
increased latency of P100-wave (P\0.0001) was
found. A signiﬁcant increase in RCT (P\0.0001)
was observed. The most prevalent features were ampli-
tude reduction in N95-wave and increased latency of
P100-wavewhichwereseenin56.7%(17/30)oftheAD
eyes.InpatientswiththeearlystagesofADandnormal
routine ophthalmological examination results,dysfunc-
tion of the retinal ganglion cells as well as of the optic
nerve is present, as detected by PERG and PVEP tests.
These dysfunctions, at least partially, explain the cause
ofvisualdisturbancesobservedinpatientswiththeearly
stages of AD.
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Introduction
Alzheimer’s disease (AD) is a progressive neurode-
generative disorder and one of the most common
causes of dementia worldwide. It is estimated that in
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about 6.4%—most of them, patients with AD (4.4%)
[1]. Due to the aging population, the number of
patients with AD is on the increase and this
contributes to a wider public health problem. The
results of Mendez et al. [2] suggest that 43% of
patients with AD have complex visual complaints.
These patients require a proper diagnosis and suitable
treatment, and the need for earlier diagnosis to slow
the progression of the disease is undisputed.
Initially, AD symptoms are discreet and generally
relate to memory deﬁcits. However, in some cases, AD
can begin with visual disturbances, including problems
with reading, blurred vision, and vague complaints of
poor vision. Such patients may have normal routine
ophthalmologicalexaminationresultsincludingnormal
visual acuity and normal fundus [3–7]. The results of
some studies suggest that in patients with AD, optic
nervedegeneration,andlossofretinalcells,speciﬁcally
disappearance of ganglion cells and their axons is
evident [8–11]. In the brain of patients with AD, the
characteristic features are beta-amyloid deposits and
neurotransmitter’ production disturbances, mainly
decreased levels of acetylcholine. Beta-amyloid depos-
itswerealsofoundintheeye[12,13],andacetylcholine
is crucial to proper functioning of retinal cells [14].
Potential value in diagnosis of visual abnormalities
in AD may be provided by electrophysiological
studies of the retina and optic nerve such as pattern
electroretinogram (PERG) and pattern visual evoked
potential (PVEP) tests. These examinations measure
the bioelectrical activity of retinal ganglion cells and
the optic nerve. To date, the available results of
PERG and PVEP tests in patients with AD are
inconclusive. Although abnormalities in PERG and in
PVEP tests have been reported in patients with AD
[15–21], normal PERG and PVEP tests results were
also observed [15, 21–25].
In some PERG examinations, amplitude reduction
was evident [15, 16]. Parisi et al. [17] showed a
signiﬁcant increase in latencies of N35-, P50-, and
N95-waves and reduction in their amplitudes. Addi-
tionally, P50-wave latency increase and amplitude
reduction in P50- and N95-waves were correlated
with a statistically signiﬁcant reduction in nerve ﬁber
layer thickness, as measured by Optical Coherence
Tomography (OCT). In PVEP examination, a latency
increase in the P100-wave was observed by Pollock
et al. [19], Kergoat et al. [21], and Partanen et al. [18].
The described studies were performed in patients who
were at different stages of AD, and most of them
examined small numbers of patients. The aim of the
current research is to evaluate retinal and optic nerve
bioelectric function in patients only in the early stages
of AD by means of PERG and PVEP tests.
Subjects and methods
Thirty patients in the early stages of AD (20 [66.7%]
women and 10 [33.3%] men), aged 54–83 (mean
72.9 ± 6.8), were diagnosed in the Neurology
Department of the Pomeranian Medical University
in Szczecin, Poland.
Each patient with AD underwent neurologic exam-
ination including magnetic resonance imaging (MRI).
All patients met the diagnostic criteria of probable AD
according to the National Institute of Neurological
and Communicative Disorders and Stroke and the
Alzheimer’s Disease Association (NINCDS-AD-
RDA) [26]. The inclusion criteria for the early stages
of AD were as follows: minimal cognitive distur-
bances in accordance with the neurologic tests and the
Mini Mental State Examination (MMSE) [27] score
above 21 points. Patients were diagnosed as having
AD from 6 months to 2 years. The ocular inclusion
criteria were as follows: taking patient’s history,
visual acuity[0.8 (Snellen chart), normal intraocular
pressure, normal kinetic visual ﬁeld, no changes in
anterior and posterior segment of the eye, and normal
color vision. Patients with systemic disorders with
known inﬂuence on the function of retina and optic
nerve as well as with poor cooperation were excluded.
PERG and PVEP tests were performed in all
patients (30 eyes—always left). Additionally, the
measurement of retinocortical time (RCT)—a param-
eter described for the ﬁrst time by Celesia et al.
[28, 29]—was obtained to provide more precise
information regarding neural conduction in the pos-
tretinal visual pathway. PERG and PVEP examina-
tions were recorded with the RetiPort (Roland
Consult) system, in accordance with the ISCEV
PERG and PVEP standards [30–33].
At the beginning of the study, 10 patients with AD
had the PERG and PVEP tests performed twice in two
separate sessions for checking the reproducibility of
measurements.Reproducibleresultswereobtained.Vari-
ability was determined by calculating the coefﬁcients
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123of variation (CV) for PERG and PVEP tests. Addi-
tionally, for each parameter, statistical comparisons of
mean values and variances were performed. Student t-
test and test for two variances for dependent two
samples were used. There were no statistical differ-
ences between compared parameters mentioned ear-
lier. For all measured parameters, for which the
statistically signiﬁcant abnormalities between patients
with AD and control group were obtained, the inter-
sessions variability did not exceed 10%—Table 1.
PERG test
Preparation of the patient: pupils were undilated,
appropriate refractive error correction in relation to
the eye-screen distance, binocular stimulation, and
monitoring with a TV camera (to stop the stimula-
tions when frequent blinking or ﬁxation loss) was
carried out.
Parameters of the pattern stimulation were as
follows: 2100 CRT monitor with a frame rate: 75 fps
was used, a black and white reversing checkerboard
was presented to the patient with a check size: 0.96,
luminance for the white elements: 120 cd/m
2, con-
trast: 97%, temporal frequency: 4.7 rev/s (2.35 Hz),
and central ﬁxation was used.
Electrodes: thread DTL electrodes were used as
active and a gold disk placed at the ipsilateral outer
canthi as reference, with ground—gold disk—elec-
trode placed on the forehead (Fpz).
Parameters of the recording system were as
follows: ﬁlters: 1–100 Hz, switched off notch ﬁlters,
sweep time: 250 ms, artifact reject threshold: 50 lV,
averaging: 200 sweeps. Two consecutive waveforms
were recorded, off-line averaged, and then analyzed.
Analysis of PERG parameters: amplitude and time
of the P50- and N95-waves with manual correction to
the automatic cursor placement were analyzed.
PVEP test
Preparation of the patient: pupils were undilated,
appropriate refractive error correction in relation to
the eye-screen distance, monocular stimulation, mon-
itoring with the TV camera (to stop the stimulation
when frequent blinking or ﬁxation loss) was used.
Parameters of the pattern stimulation were as
follows: 2100 CRT monitor with a frame rate: 75 fps
was used, a black and white reversing checkerboard
was presented to the patient with a check size: 140
and 160, luminance for the white elements: 120 cd/m
2
(mean luminance 55 cd/m
2), contrast: 97%, temporal
frequency: 2 rev/s (1 Hz), and central ﬁxation was
carried out.
Electrodes: active—gold disk electrode placed on
the scalp over the visual cortex at Oz with refer-
ence—gold disk electrode placed at Fz; ground—
gold disk electrode placed on the forehead at Fpz.
The electrodes were placed relative to bone land-
marks according to the international 10/20 system
[34].
Parameters of the recording system were as
follows: ﬁlters: 1–100 Hz, switched off notch ﬁlters,
sweep time: 300 ms, artifact reject threshold: 50 lV,
averaging: 100 sweeps. Two consecutive waveforms
were recorded, off-line averaged and then analyzed.
Analysis of PVEP parameters: amplitude and time
of the P100-wave with manual correction to the
automatic cursor placement were analyzed. Further-
more, in order to evaluate the bioelectrical function
Table 1 Early stages of
Alzheimer’s disease—
analysis of the mean CV for
parameters of PERG and
PVEP tests (n = 10)
n number of eyes, x
arithmetic mean value, SD
standard deviation, P
signiﬁcance level, NS not
signiﬁcant, I ﬁrst
examination, II second
examination, IT implicit
time, A amplitude, L latency
Parameter Measurement Min Max x ± SD CV [%] P value
IT P50 [ms] I 47.00 56.00 51.30 ± 3.09 6.03 NS
II 48.00 56.00 51.6 ± 2.32 4.49
A P50 [lV] I 2.63 3.90 3.61 ± 0.36 9.99 NS
II 2.91 4.39 3.84 ± 0.38 9.96
A N95 [lV] I 3.82 5.42 4.29 ± 0.44 9.73 NS
II 3.58 5.18 4.28 ± 0.39 9.03
L P100 [ms] I 106.00 120.00 111.0 ± 4.81 4.33 NS
II 107.00 119.00 110.0 ± 4.12 3.72
L P100 [ms] I 105.00 129.00 122.00 ± 7.59 6.22 NS
II 107.00 128.00 121.00 ± 7.20 5.91
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123of macular vs more peripheral regions of the retina,
differences between amplitudes of P100-wave in
patients with the early stages of AD and control
subjects after simulation with the small (160) and
large (140) check stimuli were measured. The same
comparisons were made between latencies of the
P100-wave.
Retinocortical times (RCTs) were also compared,
that is the difference between latency of P100-wave
(160 checks—RCT 1 and 140 checks—RCT 2) and
implicit time of the P50-wave, following the methods
described by Celesia et al. [28, 29].
Values of all parameters of patients with AD were
compared with the values for the control group
consisting of 30 eyes (always left) of 30 healthy
individuals matched for age, sex, and refractive errors
with AD patients.
The research was conducted in accordance with
the principles of the Declaration of Helsinki,
informed consent was obtained, and the protocol
was approved by the local Independent Ethics
Committee.
The Shapiro–Wilk test was used to evaluate
compatibility with normal distribution of analyzed
electrophysiological parameters. The PERG and
PVEP parameters in eyes of patients with AD and
eyes of the control group were compared in the
following way: (1) for normally distributed data, the
arithmetic mean and standard deviation was applied,
and Student t-test was used (2) for abnormally
distributed data, minimum–maximum value and
median was used and evaluated with the Mann–
Whitney U test. The results of PERG and PVEP tests
were considered normal when they included between
mean and ±two standard deviations (x ± 2SD) for
normally distributed data or 2.5 and 97.5 percentiles
for abnormally distributed data. The signiﬁcance
level of PERG and PVEP parameters was\0.05. For
statistical calculations, the number of eyes tested was
used, rather than the number of subjects.
Results
In the group of patients with AD, 33.0% (10/30) had
visual problems in the form of difﬁculty with reading,
writing, or undeﬁned visual disturbances, although
their optimal visual acuity for near vision was J1.0
(Jaeger charts).
The statistical analyses of PERG and PVEP results
areshowninTables 2,3,4,5,6,7.Intheeyesofpatients
with AD, PERG test revealed statistically signiﬁcant
implicit time increase in the P50-wave (P\0.03) and
reducedP50-(P\0.0001)andN95-wave(P\0.0001)
amplitudes in comparison with normal subjects
(Table 2). Analysis of individual results of PERG
parameters revealed abnormalities in 20.0% (6/30),
50% (15/30), and 56.7% (17/30) of the eyes, respec-
tively. In the eyes ofpatientswith AD inthe PVEP test
(140 and 160), a statistically signiﬁcant increase in
Table 2 Early stages of Alzheimer’s disease—analysis of the mean amplitude and mean implicit time in PERG test in comparison
with normal subjects
Amplitude [lV] P value
AD C
Min Max x ± SD Med Min Max x ± SD Med
P50 0.8 5.7 3.1 ± 1.4 2.9 2.2 8.2 4.9 ± 1.4 4.8 \0.0001*
N95 1.6 8.8 4.4 ± 1.8 4.0 3.8 11.9 7.1 ± 2.2 6.5 \0.0001**
N95/P50 ratio 0.6 2.8 1.5 ± 0.4 1.5 0.8 2.0 1.5 ± 0.2 1.5 NS
Implicit time [ms] P value
AD C
Min Max x ± SD Med Min Max x ± SD Med
P50 43.0 61.0 51.8 ± 4.1 52.5 46.0 54.0 49.9 ± 2.4 49.5 \0.03**
AD Alzheimer’s disease group, C control group, Min minimal value, Max maximal value, x arithmetic mean value, SD standard
deviation, Med median, P signiﬁcance level, NS not signiﬁcant; * normal distribution, ** not normal distribution
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123latency of the P100-wave (P\0.0001) was observed
(Tables 3, 4). Analysis of individual results in PVEP
parameters revealed abnormalities in 43.3% (13/30)
and 56.7% (17/30) of the AD eyes, respectively.
The results of comparisons of the difference
between mean amplitude/mean latency of the P100-
wave in patients with the early stages of AD and in
control individuals after stimulations of the small
(160) and large (140) checks are shown in Table 5.
Comparison of the P100-wave showed no statistically
signiﬁcant differences for the amplitudes or for the
latencies.
In eyes of patients with AD, signiﬁcant prolonged
RCT (P\0.0001) was observed in comparison with
controls (Tables 6, 7). Analysis of individual results
revealed abnormalities for RCT1 in 10.0% (3/30) and
in RCT2 in 26.7% (8/30) of the AD eyes.
Table 3 Early stages of Alzheimer’s disease—analysis of the mean amplitude and mean latency of P100 in PVEP test (140)i n
comparison with normal subjects
Amplitude [lV] P value
AD C
Min Max x ± SD Med Min Max x ± SD Med
P100 0.8 3.5 1.9 ± 0.7 2.0 0.8 6.4 2.2 ± 1.4 1.8 NS
Latency [ms] P value
AD C
Min Max x ± SD Med Min Max x ± SD Med
P100 100.0 129.0 113.9 ± 7.6 110.5 92.0 116.0 105.0 ± 5.6 103.5 \0.0001**
AD Alzheimer’s disease group, C control group, Min minimal value, Max maximal value, x arithmetic mean value, SD standard
deviation, Med median, P signiﬁcance level, NS not signiﬁcant, ** not normal distribution
Table 4 Early stages of Alzheimer’s disease—analysis of the mean amplitude and mean latency of P100 in PVEP test (160)i n
comparison with normal subjects
Amplitude [lV] P value
AD C
Min Max x ± SD Med Min Max x ± SD Med
P100 0.9 6.9 2.5 ± 1.4 2.1 0.6 8.7 2.5 ± 1.6 2.0 NS
Latency [ms] P value
AD C
Min Max x ± SD Med Min Max x ± SD Med
P100 105.0 139.0 123.0 ± 7.6 126.0 95.0 124.0 114.1 ± 7.1 115.5 \0.0001**
AD Alzheimer’s disease group, C control group, Min minimal value, Max maximal value, x arithmetic mean value, SD standard
deviation, Med median, P signiﬁcance level, NS not signiﬁcant, ** not normal distribution
Table 5 Difference between mean amplitude/latency of the
P100-wave in patients with the early stages of AD and mean
amplitude/latency of the P100-wave in normal subjects after
stimulation with the small (160) and large (140) check stimuli
Amplitude [lV] P value
Min Max x ± SD Med
P100 (140) -5.4 2.3 -0.3 ± 1.7 -0.2 NS
P100 (160) -7.1 5.7 0.0 ± 2.2 -0.2
Latency [ms] P value
Min Max x ± SD Med
P100 (140) -8.0 26.0 7.0 ± 7.5 7.0 NS
P100 (160) -18.0 28.0 8.0 ± 9.8 7.5
Min minimal value, Max maximal value, x arithmetic mean
value, SD standard deviation, Med median, P signiﬁcance
level, NS not signiﬁcant
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123In Fig. 1, the frequency of abnormalities in PERG
and PVEP tests in patients with the early stages of
AD is shown.
Examples of abnormal PERG and PVEP record-
ings in patients with AD are presented in Figs. 2, 3, 4.
In Fig. 5, scatter-plots of PERG (amplitudes of P50-
and N95-waves and implicit time of P50-wave) and
PVEP (latencies of P100-wave) as a function of age
are shown.
Discussion
The results of our study strongly suggest, for the ﬁrst
time, that in patients with the early stages of AD,
bioelectrical dysfunction of retinal ganglion cells and
the optic nerve is present and this is registered by
Table 6 Early stages of Alzheimer’s disease—analysis of RCT 1 in comparison with normal subjects
RCT 1 [LP100 (160)—LP50] P value
AD C
Min Max x ± SD Med Min Max x ± SD Med
58.0 89.0 72.2 ± 6.4 72.5 48.0 78.0 64.2 ± 7.0 65.0 \0.0001*
RCT retinocortical time, AD Alzheimer’s disease group, C control group, Min minimal value, Max maximal value, x arithmetic mean
value, SD standard deviation, Med median, P signiﬁcance level, * normal distribution
Table 7 Early stages of Alzheimer’s disease—analysis of RCT 2 in comparison with normal subjects
RCT 2 [LP100 (140)—LP50] P value
AD C
Min Max x ± SD Med Min Max x ± SD Med
49.0 76.0 62.1 ± 6.5 60.5 42.0 70.0 55.1 ± 5.9 54.0 \0.0001*
RCT retinocortical time, AD Alzheimer’s disease group, C control group, Min minimal value, Max maximal value, x arithmetic mean
value, SD standard deviation, Med median, P signiﬁcance level, * normal distribution
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Fig. 1 Early stages of
Alzheimer’s disease—
frequency of abnormalities
in PERG and PVEP tests
(A amplitude, L latency,
RCT retinocortical time)
Fig. 2 PERG—P50-wave latency delay and reduced ampli-
tudes of P50- and N95-wave in a patient with the early stage of
Alzheimer’s disease (below) in comparison with the normal
control (above)
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123PERG and PVEP tests. Previously, some researchers
[15–21] also reported abnormalities in PERG and
PVEP tests in patients with AD but they considered
different stages of this disease, with the exception of
one study in which reduced amplitude of P100 in
PVEP examination in patients with the early stages of
AD was detected [20]. Furthermore, PERG and
PVEP tests were usually performed on small numbers
of patients and in which between-group comparisons
were made.
It is worthwhile to note that recording of PERG and
PVEP tests in patients with AD is not easy because of
the possible secondary effects of defocus or other
behavioral problems. To minimize these problems, in
our study, appropriate selection of patients was made.
We performed electrophysiological tests only in early
Fig. 3 PVEP (140)—P100-wave latency delay in a patient
with the early stage of Alzheimer’s disease (below)i n
comparison with the normal control (above)
Fig. 4 PVEP (160)—P100-wave latency delay in a patient
with the early stage of Alzheimer’s disease (below)i n
comparison with the normal control (above)
P50 Implicit time [PERG]
30
40
50
60
70
Age [years]
I
m
p
l
i
c
i
t
 
t
i
m
e
 
[
m
s
]
P50 amplitudes [PERG]
0
2
4
6
8
10
Age [years]
A
m
p
l
i
t
u
d
e
 
[
u
V
]
N95 amplitudes [PERG]
1
3
5
7
9
11
13
15
Age [years]
A
m
p
l
i
t
u
d
e
 
[
u
V
]
P100 latencies [PVEP 1 deg 4 min]
90
100
110
120
130
140
Ages [years]
L
a
t
e
n
c
y
 
[
m
s
]
P100 latecies [PVEP 16 min]
90
100
110
120
130
140
150
50 55 60 65 70 75 80 85
50 55 60 65 70 75 80 85
50 55 60 65 70 75 80 85
50 55 60 65 70 75 80 85
Age [years]
L
a
t
e
n
c
y
 
[
m
s
]
50 55 60 65 70 75 80 85
Fig. 5 Early stages of Alzheimer’s disease—scatter-plot of
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123stages of AD when patients had minimal disturbances
of cognitive function and their cooperation was very
good. PERG and PVEP examinations were recorded
by the ﬁrst author of presented manuscript who was
familiar with the PERG and PVEP procedures and
understood possible difﬁculties with cooperation in
patients with AD.
In the present study, in patients with the early
stages of AD, we noticed statistically signiﬁcant
abnormalities in PERG and in PVEP examinations
(PERG: implicit time increase in P50-wave
(P\0.04), reduced amplitudes of P50- and N95-
wave (P\0.0001); PVEP (checkerboard: 140 and
160): latency increase in P100-wave (P\0.0001). We
also found statistically prolonged RCT (P\0.0001).
What is worthwhile to note, amplitude reduction of
N95-wave in PERG examination, and latencyincrease
of P100-wave in PVEP (160) examination was found
in more than 50% of analyzed AD eyes (Fig. 1).
N95-wave provides a measure of ganglion cells
function but approximately 70% of the P50-wave is
also generated by the ganglion cells [35]. The
remaining 30% may be generated more distally [36,
37]. Amplitude reduction and implicit time shorten-
ing of the P50-wave are indicators of ganglion cells/
optic nerve dysfunction. P50-wave implicit time
increase is not a characteristic feature of optic nerve
or ganglion cell disease [35, 37]—it may be seen in
some maculopathies such as in macular edema [38].
In our group of patients with the early stages of
AD, the observed reduced amplitude of N95-wave
conﬁrms the dysfunction of ganglion cells, whereas
reduced amplitude and implicit time increase in P50-
wave may be related to dysfunction, not only of the
ganglion cells, but also of the outer layers of the
retina in relation to the ganglion cells.
P-100 wave reﬂects the bioelectrical function of
the optic nerve [37, 39]. Latency increase in P100-
wave may be a subclinical feature of optic nerve
dysfunction, and it may be detected without any
pathological changes in routine ophthalmological
examination [40]. The results obtained in patients
with the early stages of AD showed increased latency
of P100 and consistent with optic nerve dysfunction.
RCT may independently indicate neural conduc-
tion in the postretinal visual pathway [28, 29]. An
example conﬁrming this hypothesis is normal RCT
but abnormal PERG and PVEP tests in patients with
maculopathies. In this case, latency increase in PVEP
test might be a consequence of abnormalities
revealed in the PERG test.
In the group of patients with the early stages of
AD, latency increase in P50- and P100-waves and
prolonged RCT without any clinical signs of macul-
opathies were observed. Therefore, results of our
study suggest that abnormalities in PERG/PVEP tests
and in RCT could be connected not only with
impaired neural conduction in the visual pathway
including the optic nerve but also with dysfunction of
the inner retinal layers. Previously, prolonged RCT
was observed in neuropathies in the course of some
diseases, e.g., in multiple sclerosis [29] and glaucoma
[41]. According to Lam [39], different sizes of the
check stimulus in PVEP test stimulate different parts
of the retina. The large check stimulus elicits more
parafoveal response and small check stimulus elicits
a mainly foveal response. We also investigated the
difference in PVEP examination between stimulation
in the foveal and parafoveal region in patients with
the early stages of AD.
Comparative analysis between amplitudes and
latencies (Tables 4, 5) after large (140) and small
(160) checks stimulation showed no statistically sig-
niﬁcantdifferences. Lack of regional differentiation in
PVEP responses between the foveal and parafoveal
part of the retina shows that in the early stages of AD,
the optic nerve ﬁbers can be evenly disturbed.
Most authors [2, 22] suggest that in patients with
AD, visual disturbances are caused by neuropatho-
logical changes in the visual cortex. The results
obtained in the current study show that visual
disturbances in AD may also be related to the retinal
ganglion cells and optic nerve dysfunction.
The possible causes of visual abnormalities men-
tioned earlier may be due to beta-amyloid and
amyloid precursor protein (APP) deposits in the
retina and optic nerve as well as retinal neurotrans-
mitter deﬁcits, mainly acetylcholine [42–44].
Some researchers observed the cytotoxic inﬂuence
of aggregated beta-amyloid on neurons that express
neurotransmitters, including acetylcholine [45]. Ber-
isha et al. [8] observed that patients with early AD
showed a signiﬁcant thinning of retinal nerve ﬁber
layer (RNFL), as measured by OCT. This may be
connected with beta-amyloid aggregation and neuro-
nal degeneration in the retina.
Acetylcholine plays an important role in the
process of vision because it is essential for the proper
118 Doc Ophthalmol (2010) 121:111–121
123functioning of retinal cells. Acetylcholine receptors
are distributed predominantly in the inner retinal
layers and also, but in smaller densities, in the outer
layers of the retina [14, 46]. The indicators of
dysfunction to the ganglion cells and to the outer
layers of the retina are changes observed in N95-
wave and in P50-waves of PERG examination,
respectively.
Additional evidence suggesting that acetylcholine
may play a role in observed abnormalities in patients
with AD comes from a monkey study investigating
the inﬂuence of acetylcholine level on PERG exam-
ination [47]. Administration of an acetylcholine
precursor caused increased amplitudes in PERG test.
In another studies, the effect of acetylcholine level
was also explored on ﬂash visual potentials (FVEP)
recordings in healthy subjects [48, 49]. Administra-
tion of galanthamine—an inhibitor of the enzyme that
breaks down acetylcholine—resulted in increased
amplitudes [48] while the administration of the
acetylcholine antagonist, scopolamine, caused reduc-
tion of P2-wave amplitude in FVEP test [49].
Thus, in patients with the early stages of AD, the
dysfunction of retinal ganglion cells and the optic
nerve as measured by PERG and PVEP examinations
may be associated with the beta-amyloid deposits and
neurotransmitters deﬁcits.
In the current study group, visual complaints were
observed in 1/3 (10/30) analyzed patients with the
early stages of AD. Furthermore, the majority (7/10)
had abnormalities in electrophysiological tests. In the
remaining patients without visual symptoms, electro-
physiological abnormalities are an indicator of con-
ductive deterioration in visual pathway and can be a
subclinical ocular feature of AD.
In the future, it would be worth to perform
additional research in patients with the early stages
of AD to include results of PERG responses to
different check sizes (similar to the VEP recordings)
and to correlate the data with OCT. In the present
study in only a few patients in the early stages of AD,
the OCT was performed, because the OCT equipment
was available at the end of our research project. What
is important, all these patients had normal OCT
results, but abnormal PERG and PVEP examinations.
Therefore, these examples suggest that dysfunction of
the ganglion cells measured by electrophysiological
tests precedes the structural changes in the ganglion
cell layer. We believe that it might be true, because in
other studies [24, 50], changes in OCT were observed
in advanced but not in the early stages of AD.
The dysfunction of retinal ganglion cells and the
optic nerve may, at least partially, explain the cause
of visual disturbances reported by patients with the
early stages of Alzheimer’s disease and with appar-
ently normal eyes.
This dysfunction might be a characteristic feature
of AD and may be useful in the differential diagnosis.
Further investigations in a larger group of patients
with AD and also in patients with other types of
dementia are necessary to conﬁrm our suggestion.
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Creative Commons Attribution Noncommercial License which
permits any noncommercial use, distribution, and reproduction
in any medium, provided the original author(s) and source are
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